Naloxone hydrochloride injection by Hospira recall due to potential presence of particulate matter

0

…potential presence of embedded and loose particulate matter on the syringe plunger” FDA (2018).

FDA report “Hospira, Inc., a Pfizer company, is voluntarily recalling lots 72680LL and 76510LL of Naloxone Hydrochloride Injection, USP, 0.4 mg/mL, 1 mL in 2.5 mL, Carpuject Single-use cartridge syringe system (NDC 0409-1782-69), to the hospital/institution level due to the potential presence of embedded and loose particulate matter on the syringe plunger.

In the event that impacted product is administered to a patient, the patient has a low likelihood of experiencing adverse events ranging from local irritation, allergic reactions, phlebitis, end-organ granuloma, tissue ischemia, pulmonary emboli, pulmonary dysfunction, pulmonary infarction, and toxicity.To date, Hospira, Inc. has not received reports of any adverse events associated with this issue for these lots.”

Full Alert



Share.

Comments are closed.